1. Pink Sheet

Genentech Aims For Broad Access To Avastin In Cervical Cancer, But Needs To Figure Out How To Get There

 
• By Emily Hayes

FDA approval is fifth indication for Roche/Genentech’s Avastin. Number of cases in the U.S. is low and set to decline with better prevention, but disease is considered a major global health problem.

Genentech Inc. intends to make Avastin (bevacizumab) broadly accessible worldwide in cervical cancer, though the details have yet to be worked out market-by-market.

“Ultimately, what we are striving to do is to make this treatment available to all women who need it,” Philippe...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D